Surface Protein gp120 - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Surface Protein gp120 - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Surface Protein gp120 - Pipeline Review, H2 2016', provides in depth analysis on Surface Protein gp120 targeted pipeline therapeutics. 

The report provides comprehensive information on the Surface Protein gp120, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Surface Protein gp120 targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Surface Protein gp120
- The report reviews Surface Protein gp120 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Surface Protein gp120 targeted therapeutics and enlists all their major and minor projects 
- The report assesses Surface Protein gp120 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Surface Protein gp120 targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Surface Protein gp120
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Surface Protein gp120 development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Surface Protein gp120 Overview 8
Therapeutics Development 9
Surface Protein gp120 - Products under Development by Stage of Development 9
Surface Protein gp120 - Products under Development by Therapy Area 10
Surface Protein gp120 - Products under Development by Indication 11
Surface Protein gp120 - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Surface Protein gp120 - Products under Development by Companies 14
Surface Protein gp120 - Products under Development by Universities/Institutes 16
Surface Protein gp120 - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Surface Protein gp120 - Companies Involved in Therapeutics Development 24
GlaxoSmithKline Plc 24
Osel, Inc. 25
Sanofi Pasteur SA 26
TeneoBio Inc 27
United Biomedical, Inc. 28
ViiV Healthcare Limited 29
Surface Protein gp120 - Drug Profiles 30
Abzentek - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
AIDSVAX B/B + ALVAC-HIV vCP1521 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Biologic for Infectious Disease - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
BMD-101 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
BMD-104 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
BMS-585248 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
DS-003 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
fostemsavir tromethamine - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
HIV [strains C1086 + TV1] (bivalent) vaccine - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
HIV vaccine - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
HIV vaccine - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
HIV vaccine 1 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
HIV-1 vaccine - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
HNG-156 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
M-48U1 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Monoclonal Antibodies to Inhibit GP120 for HIV - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Monoclonal Antibodies to Inhibit Gp120 for HIV-1 Infection - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Monoclonal Antibody to Inhibit Glycoprotein 120 for HIV - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Recombinant Peptide to Inhibit gp120 for HIV-1 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Recombinant Protein to Target gp120 for HIV-1 Infections - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
VCP-2438 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
VRC-01LS - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Surface Protein gp120 - Dormant Projects 59
Surface Protein gp120 - Discontinued Products 62
Surface Protein gp120 - Featured News & Press Releases 63
May 18, 2016: Large-scale HIV vaccine trial to launch in South Africa 63
Jan 07, 2016: National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology 64
Dec 02, 2015: Abzyme Research Foundation's Inaugural ENDHIV BALL Launches $3 Million Fund for New Therapeutic HIV Vaccine Trial 64
Jul 21, 2015: Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients 65
Jul 08, 2015: Scripps research-designed drug candidate significantly reduces HIV reactivation rate 66
Feb 25, 2015: 48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation 67
Oct 03, 2014: Bristol-Myers Squibb Presents Data of BMS-663068 at IDWeek 2014 Showcasing Continued Innovation in Virology 68
Jul 30, 2014: Dissolvable fabric loaded with medicine might offer faster protection against HIV 69
Mar 05, 2014: Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients 70
May 06, 2013: Duke Researchers Report Additional Information From Phase III HIV Vaccine Trial In Thailand 71
Dec 06, 2012: Vaginal microbicide gel may offer a promising strategy for prevention and protection against HIV transmission 72
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by GlaxoSmithKline Plc, H2 2016 24
Pipeline by Osel, Inc., H2 2016 25
Pipeline by Sanofi Pasteur SA, H2 2016 26
Pipeline by TeneoBio Inc, H2 2016 27
Pipeline by United Biomedical, Inc., H2 2016 28
Pipeline by ViiV Healthcare Limited, H2 2016 29
Dormant Projects, H2 2016 59
Dormant Projects (Contd..1), H2 2016 60
Dormant Projects (Contd..2), H2 2016 61
Discontinued Products, H2 2016 62